drugset / Trial / NCT06843460

A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)

NCT06843460

Phase 1 Completed 24 enrolled Merck Sharp & Dohme LLC
RandomizedSequentialDouble-blindTreatment

Summary

The goal of this study is to learn about the safety of 2 different amounts of sotatercept and if healthy Chinese people tolerate them. The study will also measure what happens to sotatercept in a person's body over time (pharmacokinetic or PK study).

Timeline

Start
2023-11-22
Primary completion
2024-05-21
Completion
2024-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotatercept Protein / enzyme biologic 0.3 mg/kg Subcutaneous
Subject Sotatercept Protein / enzyme biologic 0.7 mg/kg Subcutaneous

Indications

No indication recorded.